Literature DB >> 9838072

Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene.

D S O'Keefe1, S L Su, D J Bacich, Y Horiguchi, Y Luo, C T Powell, D Zandvliet, P J Russell, P L Molloy, N J Nowak, T B Shows, C Mullins, R A Vonder Haar, W R Fair, W D Heston.   

Abstract

Prostate-specific membrane antigen (PSMA) is a 100 kDa type II transmembrane protein with folate hydrolase and NAALAdase activity. PSMA is highly expressed in prostate cancer and the vasculature of most solid tumors, and is currently the target of a number of diagnostic and therapeutic strategies. PSMA is also expressed in the brain, and is involved in conversion of the major neurotransmitter NAAG (N-acetyl-aspartyl glutamate) to NAA and free glutamate, the levels of which are disrupted in several neurological disorders including multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease and schizophrenia. To facilitate analysis of the role of PSMA in carcinoma we have determined the structural organization of the gene. The gene consists of 19 exons spanning approximately 60 kb of genomic DNA. A 1244 nt portion of the 5' region of the PSMA gene was able to drive the firefly luciferase reporter gene in prostate but not breast-derived cell lines. We have mapped the gene encoding PSMA to 11p11-p12, however a gene homologous, but not identical, to PSMA exists on chromosome 11q14. Analysis of sequence differences between non-coding regions of the two genes suggests duplication and divergence occurred 22 million years ago.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9838072     DOI: 10.1016/s0167-4781(98)00200-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  39 in total

1.  Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.

Authors:  Ziyue Karen Jiang; Makoto Sato; Liu H Wei; Chinghai Kao; Lily Wu
Journal:  Cancer Res       Date:  2011-09-20       Impact factor: 12.701

2.  Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.

Authors:  Makoto Sato; Mai Johnson; Liqun Zhang; Baohui Zhang; Kim Le; Sanjiv S Gambhir; Michael Carey; Lily Wu
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

Review 3.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

4.  Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction.

Authors:  Rebecca E Conway; Nenad Petrovic; Zhong Li; Warren Heston; Dianqing Wu; Linda H Shapiro
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 5.  Imaging and evaluation of patients with high-risk prostate cancer.

Authors:  Marc A Bjurlin; Andrew B Rosenkrantz; Luis S Beltran; Roy A Raad; Samir S Taneja
Journal:  Nat Rev Urol       Date:  2015-10-20       Impact factor: 14.432

6.  Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate.

Authors:  Takahito Nakajima; Makoto Mitsunaga; Neil H Bander; Warren D Heston; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2011-07-27       Impact factor: 4.774

Review 7.  Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges.

Authors:  Martin K Bakht; So Won Oh; Hyewon Youn; Gi Jeong Cheon; Cheol Kwak; Keon Wook Kang
Journal:  Nucl Med Mol Imaging       Date:  2016-08-06

8.  The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer.

Authors:  Prasanna Santhanam; Jonathon Russell; Lisa M Rooper; Paul W Ladenson; Martin G Pomper; Steven P Rowe
Journal:  Med Oncol       Date:  2020-10-09       Impact factor: 3.064

Review 9.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

Review 10.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.